Remission and time of resolution of nail psoriasis during infliximab therapy
Authors:
- Luca BianchiLBLuca Bianchi
- Antonio BergaminABAntonio Bergamin
- Catia de FeliceCFCatia de Felice
- Elisabetta CapriottiECElisabetta Capriotti
- Sergio ChimentiSCSergio Chimenti
- 1 April 2005
- journal article
- other
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 52 (4) , 736-737
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Nail psoriasis severity index: a useful tool for evaluation of nail psoriasisJournal of the American Academy of Dermatology, 2003
- Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgarisJournal of the American Academy of Dermatology, 2003
- Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trialThe Lancet, 2001
- Management of nail psoriasisClinical and Experimental Dermatology, 2000
- Psoriasis of the Nails Associated with Disability in a Large Number of Patients: Results of a Recent Interview with 1,728 PatientsDermatology, 1996